Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Evaluation of the expression levels of BRAFV600E mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay

Fig. 4

Detection of the BRAFV600E mutation in FFPE samples using DNA sequencing. Sanger DNA sequencing was used as a reference method to detect the BRAFV600E mutation in clinical FFPE specimens from patients with thyroid cancer and non-malignant thyroid disease. a Sequencing chromatogram showing two peaks (red and green) at the nucleotide position of interest for a sample with the BRAFV600E mutation (B7020), and b single peak (red) for a sample with wild type BRAF only (B6659)

Back to article page
\